SCDM Updated CCDM Exam Questions and Answers by lucca

The main issue with this approach is thatno time has been allocated for ongoing maintenance and updates of the Data Management Plan (DMP)throughout the study lifecycle.

According to theGCDMP (Chapter: Data Management Planning and Study Start-up), the DMP is aliving document— it must be continuously maintained and updated as study procedures evolve, particularly afterprotocol amendments, database modifications, or changes in data validation or reconciliation procedures.

Budgeting only for initial creation (forty hours) over three months ignores the substantial effort required forDMP version control, stakeholder communication, and mid-study updates. These updates are mandatory to maintain compliance withICH E6 (R2) GCP Section 5.5.3, which requires that all procedural documentation accurately reflect current practices.

Thus, the problem is not the time allocated for creation but thelack of planning for ongoing maintenance.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Plan (DMP), Section 5.3 – DMP Maintenance and Version Control

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 – Documentation of Data Handling Procedures

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations – Section on Documentation Updates

The best long-term corrective and preventive action (CAPA) in this situation is acombination of user re-training, communication, and routine monitoring— as described inOption B.

According to theGCDMP (Chapter: Electronic Data Capture Systems)andFDA 21 CFR Part 11, user credentials and electronic signatures in clinical systems arelegally bindingand must be used only by the assigned individual. Simultaneous log-ins under the same credentials often indicatecredential sharing, acompliance violationthat must be addressed through user education, reinforced security policies, and ongoing system oversight.

While technical controls (option A) may be considered, behavioral and procedural reinforcement are the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA practices.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 7.1 – User Access, Authentication, and Training

FDA 21 CFR Part 11 – Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a)

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 – Access Control and Audit Trail Requirements

To submit study data to theFDA in CDISC SDTM format, the sponsor mustmap and transformthe collected data from the study’s operational database (e.g., EDC) intoSDTM-compliant domains.

According toGCDMP (Chapter: Standards and Data Integration)andCDISC SDTM Implementation Guide, this process includes:

Mappingraw data elements from the clinical database to SDTM domains (e.g., DM, AE, VS).

Transformingdata to comply with SDTM structural and naming conventions.

Validatingthe output using CDISC compliance tools (e.g., Pinnacle 21).

Re-entering data (B) is unnecessary, and a letter of intent (C) is not required. SDTM is explicitly accepted by FDA for both retrospective and prospective submissions, so (D) is incorrect.

Thus,option Ais correct —map and transform existing data to SDTM formatfor regulatory submission.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Standards and Data Integration, Section 5.3 – Data Transformation and CDISC Mapping

CDISC SDTM Implementation Guide, Version 3.4 – Data Conversion and Submission Requirements

FDA Study Data Technical Conformance Guide, Section 2.2 – SDTM Mapping and Validation

Standard Operating Procedures (SOPs)are formal, controlled documents that definestandardized processesto ensure clinical trials are conducted in compliance withGood Clinical Practice (GCP), the study protocol, and regulatory requirements (such as ICH and FDA).

According toGood Clinical Data Management Practices (GCDMP)andICH E6(R2) GCP, SOPs are fundamental to quality management systems. They describehowtasks are performed, ensuring consistency, accountability, and traceability across all studies and team members. Proper adherence to SOPs guarantees that data areaccurately generated, documented, and reportedin compliance with ethical and regulatory standards.

Other options serve different purposes:

SAP (B)defines statistical methodology, not compliance control.

DMP (C)focuses on study-specific data handling, not organizational compliance.

CRFs (D)are tools for data collection but do not enforce compliance by themselves.

Therefore,option A (SOP)is correct.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Quality Management and Compliance, Section 5.1 – Role of SOPs in Regulatory Compliance

ICH E6(R2) GCP, Section 2.13 and 5.1.1 – Quality Management Systems and SOP Requirements

FDA 21 CFR Part 312.50 – Sponsor Responsibilities and Compliance Systems